Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes.

The aim of this study was to determine the performance of the Dexcom G6 continuous glucose monitoring (CGM) system across three sensor wear sites in pregnant women with diabetes in the second or third trimesters. Participants with type 1 (T1D), type 2 (T2D), or gestational (GDM) diabetes mellitus were enrolled at three sites. Each wore two G6 sensors on the abdomen, upper buttock, and/or posterior upper arm for 10 days and underwent a 6-h clinic session between days 3 and 7 of sensor wear, during which YSI reference blood glucose values were obtained every 30 min.

A Novel and Easy Method to Locate and Remove First Approved Long-Term Implantable Glucose Sensors.

Eversense is a long-term implantable continuous glucose monitoring (CGM) system. Difficulty in locating and removing implanted sensors is one of the issues limiting its use. We propose using near-infrared (NIR) light to locate implanted glucose sensors.

Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes.

Aim: To compare glycaemic metrics at 3 and 6 months in patients with type 1 diabetes on a 670G hybrid closed-loop (HCL) system after using a sensor-augmented pump (SAP) for at least 3 months.

Materials And Methods: A retrospective study from a centre that has the largest number of 670G users in the United States was conducted. Data from 202 SAP users were reviewed.